Literature DB >> 10507055

Detection of polyglutamine aggregation in mouse models.

S W Davies1, K Sathasivam, C Hobbs, P Doherty, L Mangiarini, E Scherzinger, E E Wanker, G P Bates.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10507055     DOI： 10.1016/s0076-6879(99)09045-x

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN： 0076-6879            Impact factor:   1.600


× No keyword cloud information.
  18 in total

1.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription.

Authors:  J S Steffan; A Kazantsev; O Spasic-Boskovic; M Greenwald; Y Z Zhu; H Gohler; E E Wanker; G P Bates; D E Housman; L M Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease.

Authors:  John Labbadia; Helen Cunliffe; Andreas Weiss; Elena Katsyuba; Kirupa Sathasivam; Tamara Seredenina; Ben Woodman; Saliha Moussaoui; Stefan Frentzel; Ruth Luthi-Carter; Paolo Paganetti; Gillian P Bates
Journal:  J Clin Invest       Date:  2011-07-25       Impact factor: 14.808

3.  Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease.

Authors:  Christian Landles; Kirupa Sathasivam; Andreas Weiss; Ben Woodman; Hilary Moffitt; Steve Finkbeiner; Banghua Sun; Juliette Gafni; Lisa M Ellerby; Yvon Trottier; William G Richards; Alex Osmand; Paolo Paganetti; Gillian P Bates
Journal:  J Biol Chem       Date:  2010-01-19       Impact factor: 5.157

4.  Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease.

Authors:  Claudia Rose; Fiona M Menzies; Maurizio Renna; Abraham Acevedo-Arozena; Silvia Corrochano; Oana Sadiq; Steve D Brown; David C Rubinsztein
Journal:  Hum Mol Genet       Date:  2010-02-27       Impact factor: 6.150

5.  Wild type huntingtin toxicity in yeast: Implications for the role of amyloid cross-seeding in polyQ diseases.

Authors:  A I Alexandrov; G V Serpionov; V V Kushnirov; M D Ter-Avanesyan
Journal:  Prion       Date:  2016-05-03       Impact factor: 3.931

6.  Huntington's Disease-Induced Cardiac Disorders Affect Multiple Cellular Pathways.

Authors:  Girish C Melkani
Journal:  React Oxyg Species (Apex)       Date:  2016-09

7.  Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease.

Authors:  Kirupa Sathasivam; Amin Lane; Justin Legleiter; Alice Warley; Ben Woodman; Steve Finkbeiner; Paolo Paganetti; Paul J Muchowski; Stuart Wilson; Gillian P Bates
Journal:  Hum Mol Genet       Date:  2010-01-01       Impact factor: 6.150

8.  HDAC4 does not act as a protein deacetylase in the postnatal murine brain in vivo.

Authors:  Michal Mielcarek; Tamara Seredenina; Matthew P Stokes; Georgina F Osborne; Christian Landles; Linda Inuabasi; Sophie A Franklin; Jeffrey C Silva; Ruth Luthi-Carter; Vahri Beaumont; Gillian P Bates
Journal:  PLoS One       Date:  2013-11-22       Impact factor: 3.240

9.  HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration.

Authors:  Michal Mielcarek; Christian Landles; Andreas Weiss; Amyaouch Bradaia; Tamara Seredenina; Linda Inuabasi; Georgina F Osborne; Kristian Wadel; Chrystelle Touller; Rachel Butler; Janette Robertson; Sophie A Franklin; Donna L Smith; Larry Park; Paul A Marks; Erich E Wanker; Eric N Olson; Ruth Luthi-Carter; Herman van der Putten; Vahri Beaumont; Gillian P Bates
Journal:  PLoS Biol       Date:  2013-11-26       Impact factor: 8.029

10.  Quantification assays for total and polyglutamine-expanded huntingtin proteins.

Authors:  Douglas Macdonald; Michela A Tessari; Ivette Boogaard; Melanie Smith; Kristiina Pulli; Agnieszka Szynol; Faywell Albertus; Marieke B A C Lamers; Sipke Dijkstra; Daniel Kordt; Wolfgang Reindl; Frank Herrmann; George McAllister; David F Fischer; Ignacio Munoz-Sanjuan
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.